Physician profile
Michael J Keefer
NPI 1386697548
$1,630.48
in general payments reported to CMS, 2019-2025
27 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.93 · 2021: $80.82 · 2022: $517 · 2023: $466 · 2024: $286 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684 · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $683.89 |
| Education | $310.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $498.27 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $141.47 | 2021-2025 | |
| Array Biopharma INC | $124.66 | 2022-2023 | Lorbrena, Xalkori, Mektovi |
| E.R. Squibb & Sons, L.L.C. | $119.76 | 2023-2024 | Opdivo |
| Merck Sharp & Dohme LLC | $110.27 | 2024-2025 | Welireg, Keytruda, Keytruda Qlex |
| Eisai INC. | $56.64 | 2022-2024 | |
| Abbvie INC. | $48.88 | 2023-2024 | |
| Amgen INC. | $48.62 | 2021-2022 | |
| Genentech USA, INC. | $48.14 | 2019-2022 | |
| Daiichi Sankyo INC. | $45.56 | 2022-2024 | Enhertu |
| Seagen INC. | $36.87 | 2021-2022 | |
| Sirtex Medical INC | $33.73 | 2022 | |
| Celgene Corporation | $30.77 | 2022-2023 | Reblozyl |
| Beone Medicines USA, INC. | $29.99 | 2025 | Brukinsa |
| Genzyme Corporation | $28.98 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $26.49 | 2022 | |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Sumitomo Pharma America, INC. | $24.36 | 2023 | Orgovyx |
| Ipsen Biopharmaceuticals, INC | $23.42 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $20.38 | 2025 | Libtayo |
| Adc Therapeutics America, INC. | $19.72 | 2022 | |
| Lilly USA, LLC | $18.38 | 2024 | Retevmo |
| Astrazeneca Pharmaceuticals Lp | $16.75 | 2023 | Enhertu |
| Janssen Biotech, INC. | $15.46 | 2024 | Rybrevant |
| Rigel Pharmaceuticals, INC. | $13.31 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Astellas Pharma US INC | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Keefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.